Deutsche Bank
KLRA

Deutsche Bank’s Kailera Therapeutics KLRA Stock Holding History

Deutsche Bank’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
+45,648
New +$1M ﹤0.01% 2358

Other funds holding KLRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Deutsche Bank's KLRA Position: Q2 2026 in Review

Deutsche Bank opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 45,648 shares worth $1.01M. The stake represents ﹤0.01% of the portfolio and ranks #2358 among its holdings.

24 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • Deutsche Bank held 45,648 shares of Kailera Therapeutics worth $1.01M as of Q2 2026.
  • Kailera Therapeutics was a new Deutsche Bank position in Q2 2026.
  • Kailera Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2358 holding.
  • 24 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.